What's next for Ebos after the end of that Chemist Warehouse contract

What's next for Ebos after the end of that Chemist Warehouse contract
CEO John Cullity says there isn't double-digit growth to be found in animal or healthcare in Australasia. (Image: Ebos)
Rebecca Stevenson
Ebos chief executive John Cullity says the firm must hunt outside of Australasia for double-digit growth. The dual-listed healthcare and pharmaceutical marketer and wholesaler was looking for growth outside its traditional powerhouse pharmaceutical business, Cullity said. He said Ebos’s pharmacy business in NZ and Australia was solid and stable but had relatively low growth. “Double-digit growth rates are going to be very hard, so we need to broaden the group's base of earnings outside of Australia and New Zealand...

More Markets

Gentrack leads NZ sharemarket down almost 1%
Markets Market Close

Gentrack leads NZ sharemarket down almost 1%

The S&P/NZX 50 Index closed at 12,225.28, down 113.29 points or 0.92%.

Takeovers Panel will meet on NZME issue
Markets

Takeovers Panel will meet on NZME issue

The panel said in a media release today it had met on the issue of Grenon’s shareholding.

Asian stocks extend global rout
Markets

Asian stocks extend global rout

Tokyo shares fall as Trump predicts a coming US boom.

AFP 4:45pm
KMD Brands pulled into Trump trade war
Retail

KMD Brands pulled into Trump trade war

Like a lot associated with so-called ‘Liberation Day’, much remains uncertain.